A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia

Journal of Clinical Psychiatry

Volumn 68, Issue 3, 2007, Pages 368-379

  Lindenmayer, Jean Pierre ^a   Khan, Anzalee ^b   Iskander, Adel ^b   Abad, Maria T ^b   Parker, Benedicto ^b  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE MESILATE; HALOPERIDOL; OLANZAPINE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LEARNING; MALE; MEMORY; MOTOR PERFORMANCE; NEGATIVE SYNDROME; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; VIOLENCE; WEIGHT GAIN;

EID: 33947713524     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0303     Document Type: Article

References (79)

1. Carpenter WT Jr, Strauss JS, Bartko JJ. Flexible system for the diagnosis of schizophrenia: report from WHO International Pilot Study of Schizophrenia. Science 1973;182:1275-1278
2. Carpenter WT Jr. Clinical constructs and therapeutic discovery. Schizophr Res 2004;72:69-73
3. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153:321-330
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
5. Beasley CM Jr, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
6. Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-190
7. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 2003;60:553-564
8. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-1028
9. Harvey PD, Green MF, McGurk SR, et al. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003;169:404-411
10. Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry 1988;145:578-583
11. Arango C, Buchanan RW, Kirkpatrick B, et al. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry 2004;19:21-26
12. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58(suppl 10):7-12
13. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-465
14. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262
15. Kirkpatrick B, Kopelowicz A, Buchanan RW, et al. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 2000;22:303-310
16. Remington G, Chong SA, Kapur S. Distinguishing change in primary and secondary negative symptoms. Am J Psychiatry 1999;156:974-975
17. Kirkpatrick B, Buchanan RW, McKenney PD, et al. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989;30:119-123
18. Fenton WS, McGlashan TH. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992;49:179-184
19. Amador XF, Kirkpatrick B, Buchanan RW, et al. Stability of the diagnosis of deficit syndrome in schizophrenia. Am J Psychiatry 1999;156:637-639
20. Brebion G, Smith MJ, Gorman JM, et al. Memory and schizophrenia: differential link of processing speed and selective attention with two levels of encoding. J Psychiatr Res 2000;34:121-127
21. Potkin SG, Fleming K, Jin Y, et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001;21:479-483
22. Keefe RSE, Silva SG, Perkins DO, et al. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999;25:201-222
23. Kane JM, Honigfeld JG, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
24. Risch SC. Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 1996;16:11-14
25. Tandon R, Goldman R, DeQuardo JR, et al. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993;27:341-347
26. Purdon SE. Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophr Res 1999;35:S51-S60
27. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000;57:249-258
28. Sharma T, Antonova L. Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 2003;26:25-40
29. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002;53:239-248
30. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233-255
31. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001;158:176-184
32. Kay SR, Fiszben A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
33. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
34. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
36. Wagner M, Quednow BB, Westheide J, et al. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology 2005;30:381-390
37. Heaton RK and PAR Staff. Wisconsin Card Sorting Test: Computer Version 4 (WCST: CV4) Research Edition. Lutz, Fl: Psychological Assessment Resources; 1993
38. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. 2nd ed. New York, NY: Oxford University Press; 1998
39. Wechsler DA. WAIS-III, WMS-III Technical Manual. San Antonio, Tex: Psychological Cooperation; 1997
40. Helmstaedter C, Lendt M, Lux S. Verbaler Lern- und Merkfä higkeitstest (VLMT). Göttingen, Germany: Beltz Test; 2001
41. Reitan RM, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. 2nd ed. Tucson, Ariz: Neuropsychology Press; 1993
42. Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York, NY: Harcourt Brace Jovanovich; 1981
43. Gordon M. Tester for Measuring Impulsivity, Vigilance, and Distractibility. Dewitt, NY: Gordon Diagnostics System; 1985
44. Milner B. Interhemispheric differences in the localization of psychological processes in man. Br Med Bull 1971;3:272-277
45. Mitrushina MN, Boone KB, D'Elia LF. Handbook of Normative Data for Neuropsychological Assessment. New York, NY: Oxford University Press; 1999
46. Mallinckrodt CH, Clark WS, David SR. Accounting for dropout bias using mixed-effects models. J Biopharm Stat 2001;11:9-21
47. Littell RC, Milliken GA, Stroup WW, et al. SAS System for Mixed Models. Cary, NC: SAS Institute; 1996
48. Diggle PJ, Tawn JA, Moyeed RA. Model-based geostatistics. J R Stat Soc Ser C Appl Stat 1998;47:299-350
49. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York, NY: Springer-Verlag; 2000
50. Cohen, J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988
51. Statistical Package for the Social Sciences, Version 13.0. Chicago, Ill: SPSS Inc; 2004
52. Woods SW. Chlorpromazine equivalency doses for the newer atypical antipsychotics. J Clin Psychiatry 2003;64:663-667
53. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Guideline Series: Optimizing Pharmacologic Treatment of Psychotic Disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
54. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474
55. Moncrieff J. Clozapine vs conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry 2003;183:161-166
56. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-1170
57. Moller HJ, Muller H, Borison RL, et al. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-49
58. Ciudad A, Olivares JM, Gomez JC, et al. Olanzapine versus risperidone: efficacy results in negative symptoms of a one year randomized trial in outpatients with schizophrenia with prominent negative symptoms [poster]. Presented at the 24th Collegium International Neuro-Psychopharmacologicum; June 20-24, 2004; Paris, France
59. Moller HJ, Riedel M, Muller N, et al. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004;37:270-278
60. Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry 2005;162:124-129
61. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-2702
62. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 2001;58:165-171
63. Kopelowicz A, Zarate R, Tripodis K, et al. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am J Psychiatry 2000;157:987-993
64. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-995
65. Penn DL, Mueser KT, Spaulding W, et al. Information processing and social competence in chronic schizophrenia. Schizophr Bull 1995;21:269-281
66. Perlick D, Mattis S, Stastny P, et al. Negative symptoms are related to both frontal and nonfrontal neuropsychological measures in chronic schizophrenia. Arch Gen Psychiatry 1992;49:245-246
67. Mori K, Yamashita H, Nagao M, et al. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 2002;35:6-11
68. Spohn HE, Strauss ME. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 1989;98:367-380
69. Gelenberg AJ, Van Putten T, Lavori PW, et al. Anticholinergic effects on memory: benztropine versus amantadine. J Clin Psychopharmacol 1989;9:180-185
70. McGurk SR, Green MF, Wirshing WC, et al. Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia. Schizophr Res 2004;68:225-233
71. Green MF, Marshall BD Jr, Wirshing WC, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 1997;154:799-804
72. Cassens G, Inglis AK, Appelbaum PS, et al. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990;16:477-499
73. Medalia A, Gold J, Merriam A. The effects of neuroleptics on neuropsychological test results in schizophrenics. Arch Clin Neuropsychol 1988;3:249-271
74. Lustig C, Meck WH. Chronic treatment with haloperidol induces deficits in working memory and feedback effects of interval timing. Brain Cogn 2005;58:9-16
75. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296
76. Smith RC, Lindenmayer JP, Bark N, et al. Clozapine, risperidone, olanza-pine, and conventional antipsychotic drug effects on glucose, lipids and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005;8:183-194
77. Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002;10:280-291
78. Citrome L, Jaffee A, Levine J. Dosing of second-generation antipsychotic medication in a state hospital system. J Clin Psychopharmacol 2005;25:388-391
79. Perry PJ, Pfohl BM, Kelly MW. The relationship of haloperidol concentrations to therapeutic response. J Clin Psychopharmacol 1988;8:38-43